top of page

Etcembly announces breakthrough in optimising TCR assets

Successful Financing Brings in Singapore VC iGlobe Partners

Oxfordshire, UK, 15 December 2022 – Etcembly, a tech-bio company transforming the precision, scale, and speed of development of T cell receptor (TCR) immunotherapies, today announced the successful prediction and optimisation of multiple TCR assets for targeting leukamias and solid tumours. The company’s pioneering machine learning platform EMLyTM (Etcembly Machine Learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine learning based optimisation with empirical validation has facilitated the rapid decoding of disease relevant T Cell repertoires giving rise to TCRs primed for the clinic in half the development timeline.

The company has also closed a financing round, bringing on board new international investor, Singapore VC iGlobe Partners. Financial details were not disclosed.

Etcembly’s CEO and co-founder Michelle Teng said,

“Finding TCRs without undesirable off target effects is a big pain point in immunotherapy. The time-consuming process of exhaustive screening for each lead candidate made us rethink how we can fast track TCRs in a completely different way, so we explored the idea of engineering TCRs in silico. The platform is applicable to multiple modalities and the company has already successfully engineered TCRs for its internal program ready for cell therapies and we are now moving into the biologics space. I’m delighted that iGlobe Partners has recognised the power of our innovative in silico approach and joined our investor syndicate."

Etcembly’s CTO and co-founder Jacob Hurst added,

“EMLyTM can adeptly interrogate our massive database of TCR repertoires. Not only can we expertly find new TCRs, but we can also re-engineer existing TCR based assets to improve affinity and potency. Importantly, our approach is haplotype independent, which means we can help companies with the Holy Grail of developing immunotherapies that have global therapeutic value. We see EMLyTM as the oracle of immunotherapy for our pharmaceutical partners.”

Soo Boon Koh, Founder and Managing Partner at iGlobe Partners said,

“At iGlobe Partners we unearth, invest, and grow start-ups into global leaders. We have a strong track record of scaling game-changing innovations and see tremendous potential to do that with EMLyTM. We have been impressed by the speed at which the platform has been able to predict and optimise TCR assets.”

Etcembly’s Board Director, and founder of Immunocore and Adaptimmune, Bent Jakobsen, added,

“Immunotherapy has advanced massively as a therapeutic approach since I founded Immunocore and Adaptimmune. It now brings great benefit to patients and society and holds immense promise for further developments. TCRs may prove to be the most important component for realising this potential, but deciphering their specificities is amongst the most complex challenges in biology. Etcembly’s platform has now broken the last barrier by enabling sourcing from the full repertoire of possible TCRs. Put simply, EMLyTM enables drug hunters to see further, move faster, and be more successful.”

- Ends –

Media contacts:


CEO Michelle Teng

+44 7731854522

CBO Scott Cuthill

+44 7585760228

Scius Communications

Katja Stout

+44 7789435990

Daniel Gooch

+44 774 787 5479

About Etcembly

Etcembly is a UK biotech company harnessing the power of the adaptive immune system to transform the precision, scale and speed of clinical development of immunotherapeutics.

T Cell receptors (TCRs) constitute one of the most promising classes of emerging immunotherapies. Until now, they have remained one of the most complex facets of immune biology, hindering the effective delivery of immunotherapies to patients.

Etcembly takes a novel, multi-modal approach to engineering optimal TCRs for targeted patient populations. The company’s pioneering machine learning platform EMLyTM combines in silico prediction with in vitro optimisation. The unification of AI driven design with empirical validation allows the rapid decoding of T cell repertoires leading to TCRs primed for the clinic.

The Company eliminates a significant bottleneck for its industry partners to create safe and potent therapeutic assets and accelerating drug development timelines in indications across oncology, autoimmunity and infectious diseases.

The Company was founded in 2020 and is headquartered in Oxfordshire, UK. Our partners include Illumina, Great Ormond Street Hospital, Zelluna AS, SingHealth, National Cancer Centre Singapore and Imperial College London. For more information, please visit, and follow us on Twitter and LinkedIn.



bottom of page